June 12 – 17, 2022
Sanofi co-developed a SARS-CoV-2 recombinant protein vaccine for the prophylaxis of COVID-19 disease based on recombinant protein antigens adjuvanted with AS03 from GSK. The recombinant protein used leverages the safe and effective platform used to produce Flublok/Supemtek® (Flublok), the first licensed recombinant seasonal influenza vaccine. The manufacturing process of Flublok utilizes a platform based on the baculovirus expression vector system (BEVS) for the expression of recombinant hemagglutinin (rHA) proteins in insect cells. Recombinant proteins in this system are expressed using a viral vector (baculovirus Autographa californica multinucleocapsid nuclear polyhedrosis virus) that is non-pathogenic to humans. Our cell line for protein expression is a non-transformed, non-tumorigenic continuous insect cell line expressSF+® (SF+) that is derived from Spodoptera frugiperda. Once expressed, recombinant proteins are purified, formulated and filled. A schematic of this process is shown in Figure 1.
Please click Download on the upper right corner to see the full abstract.
Steven Hauser, Val Mermall, Nikolai Khramtsov, and Ronald Neeleman, "Adapting Flublok/supemtek® recombinant protein expression systems to Sars-cov-2" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/61